MedTwenty

Corrections

Correction, 27 September 2026: an earlier version of this story misstated the size of the funding round. It has been corrected.

Daily story

Healthcare Technology

Premium

Merck secures first approval for an oral PCSK9 inhibitor, reshaping the cholesterol market

Lipfendra clears the FDA as the first oral entrant in a class previously limited to injectables, with a NICE appraisal pending.

MedTwenty Editorial··5 min read

Share
A white capsule on a ceramic plate beside an amber vial
A white capsule on a ceramic plate beside an amber vial

The United States Food and Drug Administration (FDA) has granted its approval to Lipfendra, a groundbreaking oral PCSK9 inhibitor developed by pharmaceutical giant Merck. This landmark decision marks a significant turning point in the management of hypercholesterolemia, as it introduces the first orally administered compound in a therapeutic class that has, until now, exclusively comprised injectable medications requiring administration on a fortnightly or monthly basis. The move is widely anticipated to redefine patient access and compliance in a crucial area of cardiovascular health.

This regulatory endorsement by the FDA is expected to generate considerable interest across other major healthcare markets, including the United Kingdom. While the precise pricing strategy for Lipfendra in the UK has not yet been formally disclosed by Merck, anticipation is building ahead of its appraisal by the National Institute for Health and Care Excellence (NICE). The outcome of this appraisal, particularly how the committee evaluates Lipfendra against the established injectable PCSK9 inhibitors, will be pivotal in determining the speed and extent of its integration into primary care settings within the National Health Service (NHS).

Premium story

Create a free account for 3 premium articles a month

Free members read three premium pieces every month. Or go unlimited with Premium.

Create a free account

Premium

£29/month or £290/year

Unlimited premium analysis, The Analyst Note and the full archive.

Choose Premium

Already a member? Sign in

Source: Financial Times